SELLAS Life Sciences Group, Inc. (SLS) Current Ratio
- Current ratio · latest quarter: Value 18.83×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 18.83× | Current assets / current liabilities. $142.50M ÷ $7.57M ≈ 18.83× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 142.50M USD | Assets, Current |
| Current obligations | 7.57M USD | Liabilities, Current |
| Cash and equivalents | 138.34M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | Inventory, Net |
| Payables | 3.09M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $142.50M | $7.57M | $138.34M | (m) | (m) | (m) | $3.09M | (m) | 18.83× |
| 2026-03-31 | $111.17M | $6.46M | $107.10M | (m) | (m) | (m) | $3.63M | (m) | 17.22× |
| 2025-12-31 | $75.21M | $7.02M | $71.79M | (m) | (m) | (m) | $2.95M | (m) | 10.72× |
| 2025-09-30 | $49.05M | $5.92M | $44.32M | (m) | (m) | (m) | $2.31M | (m) | 8.28× |
| 2025-06-30 | $29.45M | $6.00M | $25.30M | (m) | (m) | (m) | $3.34M | (m) | 4.91× |
| 2025-03-31 | $31.97M | $6.89M | $28.40M | (m) | (m) | (m) | $3.76M | (m) | 4.64× |
| 2024-12-31 | $16.33M | $9.51M | $13.89M | (m) | (m) | (m) | $3.50M | (m) | 1.72× |
| 2024-09-30 | $24.04M | $10.61M | $21.03M | (m) | (m) | (m) | $4.55M | (m) | 2.26× |
| 2024-06-30 | $12.30M | $12.04M | $9.15M | (m) | (m) | (m) | $6.33M | (m) | 1.02× |
| 2024-03-31 | $21.50M | $14.44M | $18.41M | (m) | (m) | (m) | $7.41M | (m) | 1.49× |
| 2023-12-31 | $3.17M | $13.73M | $2.53M | (m) | (m) | (m) | $5.64M | (m) | 0.23× |
| 2023-09-30 | $5.20M | $11.73M | $3.97M | (m) | (m) | (m) | $4.34M | (m) | 0.44× |
| 2023-06-30 | $15.58M | $13.42M | $13.81M | (m) | (m) | (m) | $3.73M | (m) | 1.16× |
| 2023-03-31 | $26.02M | $15.51M | $23.90M | (m) | (m) | (m) | $3.10M | (m) | 1.68× |
| 2022-12-31 | $17.76M | $15.52M | $17.13M | (m) | (m) | (m) | $3.36M | (m) | 1.14× |
| 2022-09-30 | $22.61M | $12.55M | $21.35M | (m) | (m) | (m) | $2.13M | (m) | 1.80× |
| 2022-06-30 | $28.74M | $12.19M | $26.99M | (m) | (m) | (m) | $3.34M | (m) | 2.36× |
| 2022-03-31 | $17.84M | $10.68M | $14.25M | (m) | $1.00M | (m) | $2.84M | (m) | 1.67× |
| 2021-12-31 | $23.04M | $4.98M | $21.36M | (m) | (m) | (m) | $2.14M | (m) | 4.63× |
| 2021-09-30 | $28.97M | $5.32M | $26.28M | (m) | (m) | (m) | $2.54M | (m) | 5.45× |
| 2021-06-30 | $34.58M | $4.24M | $29.92M | (m) | (m) | (m) | $2.28M | (m) | 8.16× |
| 2021-03-31 | $31.43M | $5.97M | $28.03M | (m) | (m) | (m) | $2.35M | (m) | 5.26× |
| 2020-12-31 | $36.92M | $12.34M | $35.30M | (m) | (m) | (m) | $4.66M | (m) | 2.99× |
| 2020-09-30 | $9.33M | $4.22M | $8.20M | (m) | (m) | (m) | $1.78M | (m) | 2.21× |
| 2020-06-30 | $5.23M | $4.33M | $3.34M | (m) | (m) | (m) | $2.43M | (m) | 1.21× |
| 2020-03-31 | $8.79M | $3.63M | $6.75M | (m) | (m) | (m) | $2.62M | (m) | 2.42× |
| 2019-12-31 | $8.24M | $5.29M | $7.28M | (m) | (m) | (m) | $3.90M | (m) | 1.56× |
| 2019-09-30 | $10.21M | $5.57M | $9.12M | (m) | (m) | (m) | $3.76M | (m) | 1.83× |
| 2019-06-30 | $13.64M | $5.40M | $12.75M | (m) | (m) | (m) | $3.76M | (m) | 2.53× |
| 2019-03-31 | $3.42M | $5.80M | $2.58M | (m) | (m) | (m) | $4.64M | (m) | 0.59× |
| 2018-12-31 | $5.84M | $5.97M | $5.34M | (m) | (m) | (m) | $3.75M | (m) | 0.98× |
| 2018-09-30 | $17.81M | $12.00M | $9.97M | (m) | (m) | (m) | $7.24M | $76.00K | 1.48× |
| 2018-06-30 | $10.93M | $24.85M | $1.35M | (m) | (m) | (m) | $12.10M | $7.78M | 0.44× |
| 2018-03-31 | $13.07M | $25.75M | $3.47M | (m) | (m) | (m) | $11.45M | $8.53M | 0.51× |
| 2017-12-31 | $13.09M | $24.57M | $2.32M | (m) | (m) | (m) | $11.69M | $8.38M | 0.53× |
| 2017-09-30 | $26.64M | $28.02M | $12.91M | (m) | (m) | (m) | $211.00K | $12.17M | 0.95× |
| 2017-06-30 | $32.29M | $34.54M | $18.07M | (m) | (m) | (m) | $385.00K | $13.03M | 0.93× |
| 2017-03-31 | $42.05M | $36.27M | $27.64M | (m) | (m) | (m) | $1.16M | $12.60M | 1.16× |
| 2016-12-31 | $6.38M | $5.76M | $5.96M | (m) | (m) | (m) | (m) | (m) | 1.11× |
| 2016-09-30 | $44.46M | $42.54M | $24.51M | (m) | (m) | (m) | $894.00K | $23.72M | 1.05× |
| 2016-06-30 | $45.28M | $47.22M | $19.59M | (m) | (m) | (m) | $1.27M | $23.16M | 0.96× |
| 2016-03-31 | $37.95M | $42.22M | $34.71M | (m) | (m) | (m) | $1.02M | $3.74M | 0.90× |
| 2015-12-31 | $53.62M | $57.07M | $29.73M | (m) | (m) | (m) | $1.60M | $4.74M | 0.94× |
| 2015-09-30 | $54.19M | $37.09M | $34.81M | (m) | (m) | (m) | $1.24M | $4.17M | 1.46× |
| 2015-06-30 | $51.12M | $38.11M | $45.28M | (m) | $1.82M | $1.43M | $2.32M | $4.08M | 1.34× |
| 2015-03-31 | $57.32M | $33.96M | $52.86M | (m) | $1.06M | $637.00K | $3.29M | $3.99M | 1.69× |
| 2014-12-31 | $52.10M | $27.23M | $23.65M | (m) | (m) | $655.00K | $1.89M | $3.91M | 1.91× |
| 2014-09-30 | $28.52M | $31.59M | $24.65M | (m) | $1.44M | $450.00K | $3.36M | $4.16M | 0.90× |
| 2014-06-30 | $43.68M | $33.41M | $39.16M | (m) | $2.15M | $433.00K | $2.04M | $4.08M | 1.31× |
| 2014-03-31 | $55.78M | $26.84M | $52.43M | (m) | $1.47M | $358.00K | $1.57M | $3.10M | 2.08× |
| 2013-12-31 | $68.78M | $62.47M | $47.79M | (m) | (m) | (m) | $1.91M | $2.15M | 1.10× |
| 2013-09-30 | $56.79M | $36.51M | $51.40M | (m) | $1.54M | $425.00K | $1.89M | $1.22M | 1.56× |
| 2013-06-30 | $27.55M | $25.75M | $20.92M | (m) | (m) | $352.00K | $2.09M | $301.00K | 1.07× |
| 2013-03-31 | $27.50M | $26.38M | $17.48M | (m) | (m) | (m) | $2.12M | (m) | 1.04× |
| 2012-12-31 | $36.12M | $15.92M | $32.81M | (m) | $0.00 | $0.00 | $1.98M | $0.00 | 2.27× |
| 2012-09-30 | $16.32M | $10.06M | $15.42M | (m) | (m) | (m) | $2.21M | (m) | 1.62× |
| 2012-06-30 | $20.09M | $9.32M | $19.23M | (m) | (m) | (m) | $1.71M | (m) | 2.16× |
| 2012-03-31 | $9.09M | $27.39M | $8.70M | (m) | (m) | (m) | $2.58M | (m) | 0.33× |
| 2011-12-31 | $11.81M | $11.20M | $11.43M | (m) | (m) | (m) | $2.15M | (m) | 1.05× |
| 2011-09-30 | $16.19M | $21.46M | $15.69M | (m) | (m) | (m) | $1.46M | (m) | 0.75× |
| 2011-06-30 | $18.19M | $19.55M | $17.93M | (m) | (m) | (m) | $1.06M | (m) | 0.93× |
| 2010-12-31 | $7.04M | $5.03M | $6.89M | (m) | (m) | (m) | $724.00K | (m) | 1.40× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |